Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.58 |
| ▸ | RAB9A | P51151 | 12/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | PKM | P14618 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.51 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | METAP2 | P50579 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | METAP1 | P53582 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467532 | 0.76 | NPC1 (0.62) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30561047 | 0.75 | NPC1 (1.00) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30634854 | 0.75 | NPC1 (1.00) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL172216 | 0.75 | NPC1 (1.00) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| Water SCHEMBL9817804 | 0.73 | NPC1 (0.95) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL11088072 | 0.73 | NPC1 (0.58) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15987471 | 0.73 | NPC1 (0.58) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2991589 | 0.72 | NPC1 (0.56) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL690118 | 0.71 | CYP19A1 (0.53) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL183635 | 0.71 | METAP1 (0.56) | METAP2METAP1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | claimed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | claimed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | claimed |
| EP-1549652-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | Bayer Pharmaceuticals Corporation (US) | 2005-07-06 | — | — | EP | claimed |
| WO-2004029055-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | claimed |
| CN-103917236-A | Methods of treating proliferative diseases | NOVARTIS AG | 2014-07-09 | — | — | CN | disclosed |
| CN-101516335-B | Formulations of benzimidazolyl pyridyl ethers | NOVARTIS AG | 2014-01-08 | — | — | CN | disclosed |
| US-8129386-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| EP-2042504-B1 | Fused azole-pyrimidine derivatives | BAYER SCHERING PHARMA AG (DE) | 2011-06-01 | — | — | EP | disclosed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | disclosed |
| CN-101516335-A | Formulations of benzimidazolyl pyridyl ethers | NOVARTIS AG (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| EP-1742936-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
| WO-2005100340-A2 | POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050227958-A1 | Polycyclic pyridines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| EP-1549652-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | Bayer Pharmaceuticals Corporation (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004029055-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
| US-5965556-A | KETO-ACID AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS FOR INHIBITING THE ACTIVITY OF SERINE PROTEASE OR THIOL PROTEASE BY ADMINISTERING THE DERIVATIVE TO A MAMMAL; ALZHEIMER'S DISEASE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) | 1999-10-12 | — | — | US | disclosed |
| US-5756763-A | ENZYME INHIBITOR | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) | 1998-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | NPC1 4109/4885RAB9A 1543/4885KDM4E 3603/4885 |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | PIK3CA, PIK3CD, PIK3CG | NPC1 3989/4885RAB9A 1944/4885KDM4E 3870/4885 |
| US-20050227958-A1 | Polycyclic pyridines as potassium ion channel modulators | KCNJ2, KCNH2, KCNQ1 | NPC1 1509/4885RAB9A 3132/4885KDM4E 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.